Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

Also called NCT06825182

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06825182
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06825182. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-07 (actual); primary completion 2025-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Outpatient newly diagnosed type 2 diabetes subjects
Intervention (Drug)
Inpatient newly diagnosed type 2 diabetes subjects
Lead sponsor
Nanjing First Hospital, Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct06825182
Content hash
1d07eec7267595c4e5f8a0b4255c6530180df5c294997f057d6b08a01b6af4a4